A

proliferation of new biotech products is on its way in the next decade — and it may overwhelm the regulatory system, according to a new report from the National Academies of Sciences, Engineering, and Medicine. This comes at a time when far-reaching deregulation looms, along with a government hiring freeze.

The Trump administration, of course, has suggested that the Food and Drug Administration, among other government agencies, must cut two regulations for every one that they adopt. Dr. Scott Gottlieb, his nominee to head the FDA, may have his own ideas on the subject.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.